We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Eli Lilly, Thermo Fisher Scientific, Lockheed Martin, Boston Scientific and Canadian Pacific Railway
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 17, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. (LLY - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , Lockheed Martin Corp. (LMT - Free Report) , Boston Scientific Corp. (BSX - Free Report) and Canadian Pacific Railway Ltd. (CP - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for Eli Lilly, Thermo Fisher and Lockheed Martin
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and Lockheed Martin Corp. (LMT - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Eli Lilly's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+25.4% vs. +10.3%). The company's revenue growth is being driven by higher demand for drugs like Trulicity, Taltz and others. Lilly expects to launch four new medicines by 2023 end with Mounjaro for type II diabetes already launched and cancer drug Jaypirca already approved.
Mounjaro is off to a solid start. However, the CRL for donanemab and mirikizumab will probably delay potential launch of the candidates by several months.
Generic competition for several drugs, rising pricing pressure in the United States mainly on key drugs, Trulicity, and price cuts in some international markets like China, Japan and Europe are a few top-line headwinds. Estimates have gone up slightly ahead of Q1 results. Lilly has a mixed record of earnings surprises in the recent quarters.
Shares of Thermo Fisher Scientific have outperformed the Zacks Medical - Instruments industry over the past year (+3.0% vs. -11.1%). The company's robust year-over-year revenue growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising.
During the fourth quarter, the company opened a new bioanalytical lab in Richmond, VA to support its clinical research business. The integration of PPD is largely complete and drove strong returns for the shareholders with outstanding execution and business performance throughout the year.
However, revenues within Europe declined in the low teens. The same in Asia Pacific fell in the mid-single digits, while China registered a decline in the mid-single digits. Revenues in the rest of the world declined in high-single digits.
Shares of Lockheed Martin have outperformed the Zacks Aerospace - Defense industry over the past year (+7.0% vs. -0.1%). The company enjoys a consistent level of contract flows, and subsequent backlog growth bolsters its long-term revenue prospects.
It remains the largest U.S. defense contractor that has a steady order inflow from its leveraged presence in the Army, Air Force, Navy and IT programs. The U.S. budgetary provisions boost LMT's business. Lockheed expects to deliver 147 to 153 F-35 aircraft in 2023 and 2024.
However, America and Turkey's tiff as a result of the latter accepting Russian products may hurt its component supply from Turkey. Lockheed is facing performance issues concerning some of its products, which may hurt its results. An uncertainty revolving around the possible sanction by China on Lockheed might impact the latter.
Other noteworthy reports we are featuring today include Boston Scientific Corp. and Canadian Pacific Railway Ltd.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Eli Lilly, Thermo Fisher Scientific, Lockheed Martin, Boston Scientific and Canadian Pacific Railway
For Immediate Release
Chicago, IL – April 17, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. (LLY - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , Lockheed Martin Corp. (LMT - Free Report) , Boston Scientific Corp. (BSX - Free Report) and Canadian Pacific Railway Ltd. (CP - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for Eli Lilly, Thermo Fisher and Lockheed Martin
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and Lockheed Martin Corp. (LMT - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Eli Lilly's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+25.4% vs. +10.3%). The company's revenue growth is being driven by higher demand for drugs like Trulicity, Taltz and others. Lilly expects to launch four new medicines by 2023 end with Mounjaro for type II diabetes already launched and cancer drug Jaypirca already approved.
Mounjaro is off to a solid start. However, the CRL for donanemab and mirikizumab will probably delay potential launch of the candidates by several months.
Generic competition for several drugs, rising pricing pressure in the United States mainly on key drugs, Trulicity, and price cuts in some international markets like China, Japan and Europe are a few top-line headwinds. Estimates have gone up slightly ahead of Q1 results. Lilly has a mixed record of earnings surprises in the recent quarters.
(You can read the full research report on Eli Lilly here >>>)
Shares of Thermo Fisher Scientific have outperformed the Zacks Medical - Instruments industry over the past year (+3.0% vs. -11.1%). The company's robust year-over-year revenue growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising.
During the fourth quarter, the company opened a new bioanalytical lab in Richmond, VA to support its clinical research business. The integration of PPD is largely complete and drove strong returns for the shareholders with outstanding execution and business performance throughout the year.
However, revenues within Europe declined in the low teens. The same in Asia Pacific fell in the mid-single digits, while China registered a decline in the mid-single digits. Revenues in the rest of the world declined in high-single digits.
(You can read the full research report on Thermo Fisher Scientific here >>>)
Shares of Lockheed Martin have outperformed the Zacks Aerospace - Defense industry over the past year (+7.0% vs. -0.1%). The company enjoys a consistent level of contract flows, and subsequent backlog growth bolsters its long-term revenue prospects.
It remains the largest U.S. defense contractor that has a steady order inflow from its leveraged presence in the Army, Air Force, Navy and IT programs. The U.S. budgetary provisions boost LMT's business. Lockheed expects to deliver 147 to 153 F-35 aircraft in 2023 and 2024.
However, America and Turkey's tiff as a result of the latter accepting Russian products may hurt its component supply from Turkey. Lockheed is facing performance issues concerning some of its products, which may hurt its results. An uncertainty revolving around the possible sanction by China on Lockheed might impact the latter.
(You can read the full research report on Lockheed Martin here >>>)
Other noteworthy reports we are featuring today include Boston Scientific Corp. and Canadian Pacific Railway Ltd.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.